On 30 May 2016, orphan designation (EU/3/16/1659) was granted by the European Commission to Orphazyme ApS, Denmark, for arimoclomol citrate for the treatment of inclusion body myositis.
In October 2020, Orphazyme ApS changed name to Orphazyme A/S.
|Disease / condition||
Treatment of inclusion body myositis
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.